The current traditional cytotoxic single agent or combination chemotherapy cannot clearly improve the overall survival rate of patients with advanced melanoma.From the current point of view, combination therapy will be one of the inevitable trends in the future development of tumor immunotherapy. So carry out this research To evaluate the objective response rate of camrelizumab combined with anlotinib hydrochloride and albumin paclitaxel in the first-line treatment of patients with advanced mucosal melanoma.
To evaluate the objective response rate of camrelizumab combined with anlotinib and nab-paclitaxel in patients with untreated advanced mucosal melanoma.